Blocks drug companies from paying rivals to delay cheaper generic and biosimilar medicines.
This bill would stop brand name drug companies from paying generic or biosimilar makers to keep cheaper versions of medicines off the market. This practice, called 'reverse payment' agreements, currently delays access to more affordable medicines. If passed, the bill would help bring lower-cost drugs to consumers sooner.
Today, brand name drug companies can make 'reverse payment' deals with generic or biosimilar companies to delay cheaper versions of medicines from entering the market. These delays mean consumers might miss out on drugs that are often 80 to 85 percent cheaper than brand name versions, affecting a market where over $449.7 billion is spent annually on retail prescription drugs. If this bill passes, such agreements would be illegal, and companies could face penalties up to three times the value of the illegal payment, aiming to bring lower-cost drugs to market sooner.
S 1096 · 119th Congress · AI Summary by gemini-2.5-flash · 8/10
Sign in to see your representatives' phone numbers
48 filings mentioned this bill
Amounts reflect total quarterly lobbying spend reported to the Senate, not bill-specific spending. Source: Senate LDA filings.